Key Points
- Director Larry Robbins sold nearly 2.0 million CVS shares on May 19 at an average price of $94.45, a transaction worth about $187.3 million. He still owns more than 6.2 million shares, so the sale reduced—but did not eliminate—his stake.
- Robbins continued selling over the next two days, including 1,018,000 shares on May 20 and 370,462 shares on May 21. The filings suggest a sizable trimming of his position rather than a full exit.
- CVS reported solid quarterly results and raised/affirmed upbeat expectations, posting $2.57 EPS versus $2.21 expected and $100.43 billion in revenue above estimates. The stock also trades near its 52-week high, and analysts maintain a generally positive view with a “Moderate Buy” consensus.
CVS Health Corporation (NYSE:CVS - Get Free Report) Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Larry Robbins also recently made the following trade(s):
- On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The stock was sold at an average price of $93.82, for a total value of $95,508,760.00.
- On Tuesday, May 19th, Larry Robbins sold 1,983,538 shares of CVS Health stock. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10.
CVS Health Price Performance
Shares of NYSE CVS opened at $93.35 on Friday. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $98.43. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The business's fifty day moving average price is $80.03 and its two-hundred day moving average price is $78.98. The firm has a market capitalization of $119.11 billion, a PE ratio of 41.12, a P/E/G ratio of 0.91 and a beta of 0.60.
CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period last year, the company earned $2.25 earnings per share. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts expect that CVS Health Corporation will post 7.44 EPS for the current year.
CVS Health Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health's dividend payout ratio (DPR) is 117.18%.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Royal Fund Management LLC boosted its stake in CVS Health by 30.2% during the first quarter. Royal Fund Management LLC now owns 88,301 shares of the pharmacy operator's stock valued at $6,342,000 after buying an additional 20,471 shares in the last quarter. Edgestream Partners L.P. bought a new position in CVS Health during the first quarter valued at about $657,000. Kentucky Retirement Systems boosted its stake in CVS Health by 25.0% during the first quarter. Kentucky Retirement Systems now owns 98,269 shares of the pharmacy operator's stock valued at $7,033,000 after buying an additional 19,633 shares in the last quarter. Bull Harbor Capital LLC bought a new position in CVS Health during the first quarter valued at about $345,000. Finally, Strategic Investment Advisors MI boosted its stake in CVS Health by 9.6% during the first quarter. Strategic Investment Advisors MI now owns 9,741 shares of the pharmacy operator's stock valued at $700,000 after buying an additional 853 shares in the last quarter. Institutional investors own 80.66% of the company's stock.
Analyst Upgrades and Downgrades
CVS has been the topic of a number of research analyst reports. Piper Sandler lowered their price target on CVS Health from $101.00 to $99.00 and set an "overweight" rating on the stock in a report on Tuesday, March 31st. Sanford C. Bernstein raised their price target on CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a report on Tuesday, May 12th. Robert W. Baird raised their price target on CVS Health from $92.00 to $94.00 and gave the company an "outperform" rating in a report on Wednesday, April 15th. DA Davidson raised their price target on CVS Health from $80.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Finally, The Goldman Sachs Group raised their price target on CVS Health from $95.00 to $97.00 and gave the company a "buy" rating in a report on Thursday, February 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.68.
Get Our Latest Analysis on CVS Health
Key Stories Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Glenview Capital said its CVS position has produced about an 80% total return since May 2024, signaling continued investor confidence in CVS’s long-term turnaround and helping reinforce the bullish case. Glenview Capital Issues Statement on CVS Health
- Positive Sentiment: Recent company-news items highlighting community programs, military support, and affordable senior housing may modestly support CVS’s brand and long-term ESG narrative, though they are unlikely to move the stock as much as the legal headlines. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
- Neutral Sentiment: Director Larry Robbins disclosed large stock sales over several days, including a roughly $187 million sale and other sizable transactions, but he still retains a large stake; the filings may be read as routine diversification rather than a full exit. SEC Form 4 filing
- Negative Sentiment: Hospitals allege CVS and its affiliates secretly captured 340B savings, which could lead to litigation costs, potential settlements, and tighter oversight of CVS’s pharmacy-benefit operations. Hospitals allege contracted CVS Health subsidiaries pocketed their 340B savings
- Negative Sentiment: Separate reports from the University of Michigan and University of Kansas hospital systems expanded the dispute and added to concerns that CVS could face multiple 340B-related lawsuits and rising legal exposure. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
